Hand allotransplantation

Gerald Brandacher, Vijay S. Gorantla, W P Andrew Lee

Research output: Contribution to journalArticle

Abstract

In the past decade, more than 100 different composite tissue allotransplantation (CTA) procedures have been performed around the world including more than 50 hand and 8 facial transplants with encouraging graft survival and excellent functional outcomes. Broader clinical application of CTA, however, continues to be hampered by requirement for long-term, high-dose, multidrug maintenance immunosuppression to prevent graft rejection mediated particularly by composite tissue allograft's highly immunogenic skin component. Medication toxicity could result in severe adverse events including metabolic and infectious complications or malignancy. Notably, unlike in solid organs, clinical success is dictated not only by graft acceptance and survival but also by nerve regeneration, which determines ultimate functional outcomes. Novel strategies such as cellular and biologic therapies that integrate the concepts of immune regulation with those of nerve regeneration have shown promising results in small and large animal models. Clinical translation of these insights to reconstructive transplantation and CTA could further minimize the need of immunosuppression and optimize functional outcomes. This will enable wider application of such treatment options for patients in need of complex reconstructive surgery for congenital deformities or devastating injuries that are not amenable to standard methods of repair.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalSeminars in Plastic Surgery
Volume24
Issue number1
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Vascularized Composite Allotransplantation
Nerve Regeneration
Hand
Graft Survival
Immunosuppression
Composite Tissue Allografts
Reconstructive Surgical Procedures
Facial Transplantation
Biological Therapy
Graft Rejection
Animal Models
Transplantation
Maintenance
Skin
Wounds and Injuries
Neoplasms
Therapeutics

Keywords

  • composite tissue
  • hand
  • immunosuppression
  • nerve regeneration
  • Transplantation

ASJC Scopus subject areas

  • Surgery

Cite this

Hand allotransplantation. / Brandacher, Gerald; Gorantla, Vijay S.; Lee, W P Andrew.

In: Seminars in Plastic Surgery, Vol. 24, No. 1, 2010, p. 11-17.

Research output: Contribution to journalArticle

Brandacher, Gerald ; Gorantla, Vijay S. ; Lee, W P Andrew. / Hand allotransplantation. In: Seminars in Plastic Surgery. 2010 ; Vol. 24, No. 1. pp. 11-17.
@article{7d30a9ff60cd4b678ed3a5762c9be7b7,
title = "Hand allotransplantation",
abstract = "In the past decade, more than 100 different composite tissue allotransplantation (CTA) procedures have been performed around the world including more than 50 hand and 8 facial transplants with encouraging graft survival and excellent functional outcomes. Broader clinical application of CTA, however, continues to be hampered by requirement for long-term, high-dose, multidrug maintenance immunosuppression to prevent graft rejection mediated particularly by composite tissue allograft's highly immunogenic skin component. Medication toxicity could result in severe adverse events including metabolic and infectious complications or malignancy. Notably, unlike in solid organs, clinical success is dictated not only by graft acceptance and survival but also by nerve regeneration, which determines ultimate functional outcomes. Novel strategies such as cellular and biologic therapies that integrate the concepts of immune regulation with those of nerve regeneration have shown promising results in small and large animal models. Clinical translation of these insights to reconstructive transplantation and CTA could further minimize the need of immunosuppression and optimize functional outcomes. This will enable wider application of such treatment options for patients in need of complex reconstructive surgery for congenital deformities or devastating injuries that are not amenable to standard methods of repair.",
keywords = "composite tissue, hand, immunosuppression, nerve regeneration, Transplantation",
author = "Gerald Brandacher and Gorantla, {Vijay S.} and Lee, {W P Andrew}",
year = "2010",
doi = "10.1055/s-0030-1253243",
language = "English (US)",
volume = "24",
pages = "11--17",
journal = "Seminars in Plastic Surgery",
issn = "1535-2188",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Hand allotransplantation

AU - Brandacher, Gerald

AU - Gorantla, Vijay S.

AU - Lee, W P Andrew

PY - 2010

Y1 - 2010

N2 - In the past decade, more than 100 different composite tissue allotransplantation (CTA) procedures have been performed around the world including more than 50 hand and 8 facial transplants with encouraging graft survival and excellent functional outcomes. Broader clinical application of CTA, however, continues to be hampered by requirement for long-term, high-dose, multidrug maintenance immunosuppression to prevent graft rejection mediated particularly by composite tissue allograft's highly immunogenic skin component. Medication toxicity could result in severe adverse events including metabolic and infectious complications or malignancy. Notably, unlike in solid organs, clinical success is dictated not only by graft acceptance and survival but also by nerve regeneration, which determines ultimate functional outcomes. Novel strategies such as cellular and biologic therapies that integrate the concepts of immune regulation with those of nerve regeneration have shown promising results in small and large animal models. Clinical translation of these insights to reconstructive transplantation and CTA could further minimize the need of immunosuppression and optimize functional outcomes. This will enable wider application of such treatment options for patients in need of complex reconstructive surgery for congenital deformities or devastating injuries that are not amenable to standard methods of repair.

AB - In the past decade, more than 100 different composite tissue allotransplantation (CTA) procedures have been performed around the world including more than 50 hand and 8 facial transplants with encouraging graft survival and excellent functional outcomes. Broader clinical application of CTA, however, continues to be hampered by requirement for long-term, high-dose, multidrug maintenance immunosuppression to prevent graft rejection mediated particularly by composite tissue allograft's highly immunogenic skin component. Medication toxicity could result in severe adverse events including metabolic and infectious complications or malignancy. Notably, unlike in solid organs, clinical success is dictated not only by graft acceptance and survival but also by nerve regeneration, which determines ultimate functional outcomes. Novel strategies such as cellular and biologic therapies that integrate the concepts of immune regulation with those of nerve regeneration have shown promising results in small and large animal models. Clinical translation of these insights to reconstructive transplantation and CTA could further minimize the need of immunosuppression and optimize functional outcomes. This will enable wider application of such treatment options for patients in need of complex reconstructive surgery for congenital deformities or devastating injuries that are not amenable to standard methods of repair.

KW - composite tissue

KW - hand

KW - immunosuppression

KW - nerve regeneration

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=79958160222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958160222&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1253243

DO - 10.1055/s-0030-1253243

M3 - Article

C2 - 21286301

AN - SCOPUS:79958160222

VL - 24

SP - 11

EP - 17

JO - Seminars in Plastic Surgery

JF - Seminars in Plastic Surgery

SN - 1535-2188

IS - 1

ER -